Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OWC Pharmaceutical Research Corp. (OWCP)
Ramat Gan, IL
OWC Pharmaceutical Research Corp., which operates through its subsidiary One World Cannabis Ltd., primarily focuses on the research and development of cannabis-based medical products. The company is dedicated to developing cannabis-derived therapies for a variety of conditions, including multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD), chronic pain, and fibromyalgia. It is also innovating with a cannabis soluble tablet delivery system. Furthermore, OWC Pharmaceutical extends its expertise by providing consulting services to both private companies and governmental agencies on international medical cannabis protocols and regulatory frameworks. Founded in 2008 as Dynamic Applications Corp., the company adopted its current name, OWC Pharmaceutical Research Corp., in December 2014. Its headquarters are located in Ramat Gan, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +900.00% | +0.00% | +99,900.00% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-120.7% Q3'19: +82.1% (vs Q3'18)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'19: +26.0% (vs Q3'18)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.0% Q3'19: +57.2% (vs Q3'18)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q3'19: -0.02× (vs Q3'18)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DISCOVER GROWTH FUND, LLC | 55.49M | 9.99% | 55.49M | — | 55.49M | — | OO | U.S. VIRGIN ISLANDS | 2021-06-21 | ↗ |
| 2 | Ehud Barzilay Holdings Ltd. | 18.00M | 20.90% | 18.00M | — | — | 10.00 | CO | or Place of Organization | 2009-05-15 | ↗ |
| 3 | Lazar Fruchter | 12.00M | 13.93% | 12.00M | — | — | — | IN | OR PLACE OF ORGANIZATION | 2009-03-17 | ↗ |
| 4 | Hussein A. Enan | 1.13M | 16.00% | 8.06M | — | 8.06M | — | IN | Delaware | 2016-06-23 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-03-23 | Sunbeam Management, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2016-12-31 | De-Saban Shmuel | Officer | — | D | Common Stock | 0 | 0.00 | — | 195,416 | — | ↗ |
| 2016-12-31 | Bignitz Mordechai | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-15 | De-Saban Shmuel | Officer | — | D | Option | 750,000 | 0.05 | 37.5K | 0 | — | ↗ |
| 2016-12-15 | Bignitz Mordechai | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-15 | BARUCH YEHUDA | Officer | — | D | Option | 7,000,000 | 0.05 | 350.0K | 0 | — | ↗ |
| 2016-01-31 | De-Saban Shmuel | Officer | — | D | Common Stock | 0 | 0.00 | — | 195,416 | — | ↗ |
| 2014-12-22 | BARUCH YEHUDA | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,120,000 | — | ↗ |
| 2014-11-07 | Turner Ziv | — | — | D | Common Stock | 0 | 0.00 | — | 2,104,480 | — | ↗ |
| 2014-11-07 | Sinai Alon | — | — | D | Common Stock | 0 | 0.00 | — | 861,250 | — | ↗ |
| 2014-11-07 | Shackelford Alan | Officer | — | D | Common Stock | 0 | 0.00 | — | 5,134,375 | — | ↗ |
| 2014-11-07 | Glazer Uri | — | — | D | Common Stock | 0 | 0.00 | — | 2,114,480 | — | ↗ |
| 2014-07-15 | Bignitz Mordechai | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-06-16 | De-Saban Shmuel | Officer | — | D | Common Stock | 0 | 0.00 | — | 135,500 | — | ↗ |
| 2011-12-23 | Shenker Jacky | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,000,000 | — | ↗ |
| 2009-06-28 | ZWEBNER ASHER | Director / Officer | S-Sale | D | COMMON STOCK | 200,000 | 0.03 | 5.0K | 0 | — | ↗ |
| 2009-06-20 | ZWEBNER ASHER | Director / Officer | S-Sale | D | COMMON STOCK | 100,000 | 0.10 | 10.0K | 200,000 | — | ↗ |
| 2009-03-16 | LAZAR FRUCHTER | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 12,000,000 | — | ↗ |
| 2008-12-10 | EHUD BARZILAY HOLDINGS LTD | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 18,000,000 | — | ↗ |
| 2008-12-01 | SPECTRUM GROUP LTD | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 21,000,000 | — | ↗ |
| 2008-11-01 | ZWEBNER ASHER | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 300,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yehuda Baruch | Chief Medical & Regulatory Affairs Officer | 112.0K | — |
| Alon Sinai | Chief Operating Officer | 94.0K | male |
| Oron Yacoby-Zeevi | Chief Scientific Officer | — | — |
| Shmuel De-Saban | Chief Financial Officer & Secretary | — | male |
| Yuval Ramot | Consultant | — | — |
| Ziv Turner | Chief Executive Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OWCP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
